scholarly journals Expression of HE4 in Endometrial Cancer and Its Clinical Significance

2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
Xiao Li ◽  
Yiping Gao ◽  
Mingzi Tan ◽  
Huiyu Zhuang ◽  
Jian Gao ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Cancer Patients ◽  
Clinical Stage ◽  
Atypical Hyperplasia ◽  
Clinicopathological Parameters ◽  
Normal Endometrium ◽  
Positive Expression ◽  
Significant Difference ◽  
Expression Rate ◽  
Degree Of Differentiation

The main aims of this study were to determine the expression of human epididymis protein 4 (HE4) in endometrial cancer and to explore the relationships between HE4 expression, clinicopathological parameters, and prognosis. Immunohistochemistry was used to detect HE4 expression in 102 cases of endometrial cancer, 30 cases of endometrial atypical hyperplasia, and 20 cases of normal endometrium. The positive expression rate of HE4 in endometrial carcinoma was 84.62%, significantly higher than 66.67% in atypical hyperplasia (P<0.05) and 15.00% in normal endometrium (P<0.0.01). With the exception of stage II, HE4 expression in endometrial cancer showed an increasing tendency with increased clinical stage (P<0.05). The positive expression rate of HE4 increased with a decrease in the degree of differentiation. A statistically significant difference was observed between the highly differentiated group and the poorly differentiated group (P<0.05). Mortality in endometrial cancer patients with high HE4 expression was significantly higher than that in patients with low HE4 expression (P<0.05). Endometrial cancer patients with high HE4 expression have a poor prognosis.

scholarly journals Analysis of CCT7 Expression and Its Clinical Significance in Endometrial Cancer

2020 ◽  
Author(s):  
Liwen Wang ◽  
Wei Zhou ◽  
Hui Li ◽  
Hui Yang ◽  
Nianchun Shan
Keyword(s):  
Endometrial Cancer ◽  
Rna Binding ◽  
Cell Function ◽  
Histological Grade ◽  
Myometrial Invasion ◽  
Nodal Metastasis ◽  
Normal Endometrium ◽  
Go Enrichment ◽  
Significant Difference ◽  
Expression Rate

Abstract Background: Endometrial cancer (EC) is a common gynecologic malignancy; myometrial invasion (MI) is a typical approach of EC spreads and an important index to assess tumor metastasis and outcome of EC patients. CCT7 is a member of the TCP1 chaperone family, involved in cytoskeletal protein folding and unfolding. In this study, the role of CCT7 in EC development was investigated. Methods: Clinical data for 87 EC cases and expression of CCT7 were analyzed. CCT7 was knocked out using siRNA-CCT7 in Ishikawa and RL95-2 cells, and their function about proliferation, apoptosis and invasion were further tested. Bioinformatics methods were used to predict the potential pathways of CCT7 in EC development.Results: The rates of CCT7-positive cells in EC and adjacent normal endometrium tissues had significant difference (67.8% vs. 51.4%, p = 0.035), and the expression rate increased from low to high pathological stage (39.7% in the I/II stage, 71.4% in the III/IV stage, p = 0.029). Similar change was found in protein level. CCT7 expression differed significantly between the deep MI group (>1/2) and the superficial MI group (≤1/2) (P = 0.039). However, there were no differences with respect to age, pathological type and histological grade. CCT7 suppression induced a function-loss in in both Ishikawa and RL95-2 cells. Bioinformatics analysis demonstrated that EC patients with lower level CCT7 expression had better Overall survival (p= 0.0081). GO enrichment indicated that “RNA binding”, “Mitochondrion”, “Translation”, and “Spliceosome” were most significantly enriched potential pathways. Five hub genes, PSMA5, PSMD14, SNRPB, SNRPG and TXNL4A, were all significantly upregulated in EC and had positive correlation with CCT7.Conclusions: CCT7 may be involved in EC development by excessively activating tumor cell function to promote MI or distant/nodal metastasis, which definitely impaired the prognosis of EC patients.

scholarly journals Analysis of CCT7 Expression and Its Clinical Significance in Endometrial Cancer

2020 ◽  
Author(s):  
Liwen Wang ◽  
Wei Zhou ◽  
Hui Li ◽  
Hui Yang ◽  
Nianchun Shan
Keyword(s):  
Endometrial Cancer ◽  
Rna Binding ◽  
Cell Function ◽  
Histological Grade ◽  
Myometrial Invasion ◽  
Nodal Metastasis ◽  
Normal Endometrium ◽  
Go Enrichment ◽  
Significant Difference ◽  
Expression Rate

Abstract Objective: Endometrial cancer (EC) is a common gynecologic malignancy; myometrial invasion (MI) is a typical approach of EC spreads and an important index to assess tumor metastasis and outcome of EC patients. CCT7 is a member of the TCP1 chaperone family, involved in cytoskeletal protein folding and unfolding. In this study, the role of CCT7 in EC development was investigated. Methods: Clinical data for 87 EC cases and expression of CCT7 were analyzed. CCT7 was knocked out using siRNA- CCT7 in Ishikawa and RL95-2 cells, and their function about proliferation, apoptosis and invasion were further tested. Bioinformatics methods were used to predict the potential pathways of CCT7 in EC development. Results: The rates of CCT7-positive cells in EC and adjacent normal endometrium tissues had significant difference (67.8% vs. 51.4%, p = 0.035), and the expression rate increased from low to high pathological stage (39.7% in the I/II stage, 71.4% in the III/IV stage, p = 0.029). Similar change was found in protein level. CCT7 expression differed significantly between the deep MI group (>1/2) and the superficial MI group (≤1/2) (P = 0.039). However, there were no differences with respect to age, pathological type and histological grade. CCT7 suppression induced a function-loss in in both Ishikawa and RL95-2 cells. Bioinformatics analysis demonstrated that EC patients with lower level CCT7 expression had better Overall survival (p= 0.0081). GO enrichment indicated that “RNA binding”, “Mitochondrion”, “Translation”, and “Spliceosome” were most significantly enriched potential pathways. Five hub genes, PSMA5, PSMD14, SNRPB, SNRPG and TXNL4 A, were all significantly upregulated in EC and had positive correlation with CCT7. Conclusions: CCT7 may be involved in EC development by excessively activating tumor cell function to promote MI or distant/nodal metastasis, which definitely impaired the prognosis of EC patients.

Serum soluble interleukin-2 receptors in epithelial ovarian cancer patients

1995 ◽  
Vol 10 (2) ◽  
pp. 75-80 ◽  
Author(s):  
N.A. Pavlidis ◽  
E. Bairaktari ◽  
J. Kalef-Ezra ◽  
C. Nicolaides ◽  
C. Seferiadis ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Serum Level ◽  
Cancer Patients ◽  
Clinical Stage ◽  
Immune Surveillance ◽  
Interleukin 2 ◽  
Patient Treatment ◽  
Response To Chemotherapy ◽  
Significant Difference ◽  
Normal Controls

The levels of soluble interleukin-2 receptors (sIL-R2) were measured in the serum of 52 patients with epithelial ovarian carcinoma as well as in 25 age and sex-matched normal controls. The mean serum level of sIL-2R was increased in 37 patients (71.2%). Comparison of these levels to those of normal controls showed a highly statistically significant difference (p<0.001). Serum sIL-2R levels were not related to histology, clinical stage or the presence of ascites (p-0.58, p=0.32 and p=0.67, respectively), nor did they follow disease activity or response to chemotherapy. However, patients with higher pretreatment sIL-2R levels (more than 1200 U/ml) were found to have a longer survival (p<0.02), possibly explained by the presence of activated lymphocytes and a better immune surveillance. We conclude that the serum level of sIL-2R: a) is elevated in ovarian cancer patients, b) has no relationship with histological subtypes, tumor burden or the presence of ascites, c) cannot serve as a valuable tumor marker for the monitoring of patient treatment, and d) has a prognostic value for survival.

scholarly journals Postmastectomy radiotherapy after neoadjuvant chemotherapy in cT1-2N+ breast cancer patients: a single center experience and review of current literature

2022 ◽  
Author(s):  
Meng Luo ◽  
Huihui Chen ◽  
Hao Deng ◽  
Yao Jin ◽  
Gui Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients ◽  
Cox Regression ◽  
Medical Center ◽  
Clinical Stage ◽  
Disease Free Survival ◽  
Her2 Overexpression ◽  
Breast Cancer Patients ◽  
Significant Difference

Abstract PurposePostmastectomy radiotherapy (PMRT) after NAC in breast cancer patients with initial clinical stage cT1−2N+, especially for those who achieved ypT1−2N0, is still controversial. This study was to evaluate the survival prognosis of cT1−2N+ patients after NAC with or without PMRT, and to discuss the selection of patients who may omit PMRT.Patients and MethodsFrom January 2005 to December 2017, 3055 female breast cancer patients underwent mastectomy in our medical center, among whom 215 patients of cT1−2N+ stage, receiving neoadjuvant chemotherapy (NAC) with or without PMRT were finally analyzed. The median follow-up duration was 72.6 months. The primary endpoint was overall survival, and the secondary endpoint was disease-free survival. Comparison was conducted between PMRT and non-PMRT subgroups.ResultsOf the 215 eligible patients, 35.8% (77/215) cT1−2N+ patients achieved ypT0−2N0 after NAC while 64.2% (138/215) of the patients remained nodal positive (ypT0−2N+). The 5-year DFS of ypT0−2N0 non-PMRT was 79.5% (95% confidence interval [CI] 63.4-95.6%). No statistically significant difference was observed between the ypT0−2N0 PMRT and non-PMRT subgroups for the 5-year DFS (78.5% vs 79.5%, p = 0.673) and OS (88.8% vs 90.8%, p = 0.721). The 5-years DFS didn’t obviously differ between the ypT0−2N0 non-PMRT subgroup and cT1−2N0 subgroup (79.5% vs 93.3%, p = 0.070). By using Cox regression model in multivariate analyses of prognosis in ypT0−2N+ PMRT subgroup, HER2 overexpression and triple-negative breast cancer were significantly poor predictors of DFS and OS, while ypN stage was significant independent predictors of OS.ConclusionAn excellent response to NAC (ypT0−2N0) indicates a sufficiently favorable prognosis, and PMRT might be omitted for cT1−2N+ breast cancer patients with ypT0−2N0 after NAC.

scholarly journals A nomogram to predict the high-risk RS in HR+/HER2-breast cancer patients older than 50 years of age

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Jing Yu ◽  
Jiayi Wu ◽  
Ou Huang ◽  
Jianrong He ◽  
Li Zhu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
High Risk ◽  
Cancer Patients ◽  
External Validation ◽  
Clinicopathological Parameters ◽  
Luminal Breast Cancer ◽  
Breast Cancer Patients ◽  
Histologic Subtype ◽  
Her2 Breast Cancer ◽  
Significant Difference

Abstract Background The 21-gene recurrence score (RS) testing can predict the prognosis for luminal breast cancer patients. Meanwhile, patients > 50 years with RS > 25 have improved survival with adjuvant chemotherapy. The current study aimed to develop a nomogram with routine parameters to predict RS. Methods We included patients diagnosed with hormone receptor (HR)-positive, human epidermal growth factor receptor-2 (HER2)-negative who underwent the 21-gene RS testing and aged > 50 years. The primary outcome was high-risk RS (> 25). Univariate and multivariate analyses were performed to identify significant predictors. A predictive nomogram based on logistic model was developed and evaluated with receiver operating characteristic (ROC) curves. The nomogram was internally validated for discrimination and calibration with bootstrapping method, and externally validated in another cohort. We then assessed the nomogram in different subgroups of patients and compared it with several published models. Results A total of 1100 patients were included. Five clinicopathological parameters were used as predictors of a high-risk RS, including tumor grade, histologic subtype, ER expression, PR expression, and Ki-67 index. The area under the curve (AUC) was 0.798 (95% CI 0.772–0.825) and optimism adjusted AUC was 0.794 (95% CI 0.781–0.822). External validation demonstrated an AUC value of 0.746 (95% CI 0.685–0.807), which had no significant difference with the training cohort (P = 0.124). Calibration plots indicated that the nomogram-predicted results were well fitted to the actual outcomes in both internal and external validation. The nomogram had better discriminate ability in patients who had tumors > 2 cm (AUC = 0.847, 95% CI 0.804–0.890). When compared with four other existing models, similar AUC was observed between our nomogram and the model constructed by discriminate Lee et al. Conclusions We developed a user-friendly nomogram to predict the high-risk RS in luminal breast cancer patients who were older than 50 years of age, which could guide treatment decision making for those who have no access to the 21-gene RS testing.

scholarly journals Evaluation of apparent diffusion coefficient in endometrial carcinoma compared to normal endometrium: a retrospective study

2021 ◽  
Author(s):  
Anu Sarah Easo ◽  
Rajeev Anand ◽  
Mini Issac
Keyword(s):  
Diffusion Coefficient ◽  
Endometrial Cancer ◽  
Retrospective Study ◽  
Apparent Diffusion Coefficient ◽  
Normal Endometrium ◽  
Adc Value ◽  
Significant Difference ◽  
Apparent Diffusion ◽  
Adc Values ◽  
Endometrial Cancers

Background: To determine whether diffusion-weighted imaging (DWI) with measurement of apparent diffusion coefficient (ADC) will help in differentiating endometrial cancer from normal endometrium and to determine whether the grades of endometrial cancer will show significant difference in ADC values.Methods: This is a retrospective study done in MOSC medical college hospital Kolencherry. on patients on whom preoperative MRI was done before hysterectomy. Cases from July 2017 to March 2021 were included. Study cases included 40 females with pathologically confirmed endometrial cancer and 30 females with pathologically proven normal endometrium in cases of uterine leiomyoma and cervical cancer. The exclusion criteria for the study were patients with endometrial cancer in whom surgery was not done within 2 weeks of MRI, patients who were treated with chemotherapy or radiotherapy before surgery, patients who had hydrometra or pyometra.Results: The mean ADC value (10−3 mm2/second) of endometrial cancer was 0.77±0.04, which was significantly lower (p<0.05) than that of normal endometrium (1.323±0.05). The ADC values of different grades of endometrial cancers did not show any statistically significant difference (p>0.05).Conclusions: Our study showed that ADC measurement can differentiate between normal endometrium and endometrial cancer. The ADC values of different grades of endometrial cancers did not show any statistically significant difference.  

scholarly journals Circulating Survivin Protein Levels in Lung Cancer Patients Treated With Platinum-Based Chemotherapy

2021 ◽  
Vol 27 ◽  
Author(s):  
Rita Puskas ◽  
Andras Bikov ◽  
Peter Horvath ◽  
Zsofia Lazar ◽  
Laszlo Kunos ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Stage Iv ◽  
Distant Metastases ◽  
Clinicopathological Parameters ◽  
Mrna Levels ◽  
Control Subjects ◽  
Survivin Protein ◽  
Platinum Based Chemotherapy ◽  
Significant Difference

The survivin protein contributes to the development and progression of tumors. Protein expression and mRNA levels correlate with clinicopathological parameters and survival of cancer patients. Our purpose was to evaluate whether circulating survivin levels have any diagnostic or predictive value in lung cancer. 118 patients with advanced stage lung cancer participated in our study. 53 suffered from adenocarcinoma (ADC), 33 from squamous cell carcinoma (SqCC), and 32 from small cell lung cancer (SCLC). We also enrolled 21 control subjects. Blood samples were collected before and after two cycles of chemotherapy. We measured survivin concentrations with ELISA. Non-parametric tests were used for analysis. We did not find significant difference in survivin levels between patients and control subjects (17.19/0–829.74/vs. 49.13/0–165.92/pg/ml; p = 0.07). We found lower survivin concentrations in patients with SqCC (0/0–171.24/pg/ml) than in those with ADC (24.94/0–626.46 pg/ml) and SCLC (45.51/0–829.74/pg/ml) (ADC vs. SqCC p &lt; 0.0001, ADC vs. SCLC p = 0.0405, SqCC vs. SCLC p &lt; 0.0001). Survivin levels were higher in stage IV patients than in patients without distant metastases (p = 0.0061), and concentrations were progressively higher with increasing number of metastatic organ sites (p = 0.04). We observed a decrease in survivin levels in ADC patients after platinum plus pemetrexed chemotherapy (26.22/0–626.46/pg/ml before vs. 0/0–114.36/pg/ml after; p = 0.01). Neither progression-free nor overall survival correlated with survivin levels at baseline. Our data imply that survivin may be involved in the development of metastases and it might be used as a biomarker of disease progression. However, circulating survivin concentrations do not predict survival of patients with lung cancer.

Anionic Glycoproteins and their Hexosamine Content in Neoplastic Patients: Relationships with the Clinical Stage and the Course of the Disease

1983 ◽  
Vol 69 (6) ◽  
pp. 503-508 ◽  
Author(s):  
Ettore Cunietti ◽  
Renato Gandini ◽  
Maria Cristina Gandini ◽  
Elisa Locatelli ◽  
Paola Viola ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Cancer Progression ◽  
Radical Surgery ◽  
Clinical Stage ◽  
Objective Response ◽  
Tumor Burden ◽  
Response To Treatment ◽  
Significant Difference ◽  
Tumor Specificity ◽  
Hexosamine Content

In 40 healthy subjects, in 47 non-cancer patients, and in 142 cancer patients, perchloric acid-soluble glycoproteins (PASG) and hexosamines were determined to investigate their tumor specificity and correlation with the tumor mass. Cancer patients were divided into three subgroups: CI, no evidence of cancer (after radical surgery); CII, locoregional disease; CIII, widespread metastatic disease. There was no statistically significant difference in PASG among normals, non-cancer and CI patients; hexosamines in non-cancer and in CI patients were higher (P < 0.002) than in normals; both PASG and hexosamines were significantly higher in CII and CIII patients than in normals (P < 0.001). In the CI group, 62% of patients who relapsed within 10 months after surgery had high hexosamine values, whereas 69% of patients who did not relapse showed normal levels (P < 0.05). PASG and hexosamines significantly increased with cancer progression and decreased when objective response to treatment was achieved. They are not tumor specific, but seem to be related to the tumor burden; hexosamines seem to have some prognostic value.

Sign in / Sign up

Export Citation Format

Share Document